Phase 2 Clinical Trial of GH001 in Postpartum Depression
- Registration Number
- NCT05804708
- Lead Sponsor
- GH Research Ireland Limited
- Brief Summary
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 10
- Is female and in the age range between 18 and 45 years (inclusive) at screening.
- Has a body mass index (BMI) in the range of 18.5 and 35 kg/m2 (inclusive) at screening.
- Meets the trial criteria for PPD as assessed by a trial psychiatrist or registered clinical psychologist.
- Has one or more first or second degree relatives with a current or prior diagnosis of bipolar disorder, psychotic disorder or other mood disorder (including MDD) with psychotic features.
- Current pregnancy resulting in termination, still-birth, pre-term delivery (before week complete gestational week 37), need for intensive care therapy of mother or child, or adoption of child away from patient.
- Has taken prohibited medication or prohibited dietary supplements within the specified timeframe prior to dosing.
- Has previously experienced a significant adverse reaction to a hallucinogenic or psychedelic drug according to the investigator's judgment.
- Has a clinically significant abnormality in physical examination, vital signs, ECG, or clinical laboratory parameters which renders the patient unsuitable for the trial according to the investigator's judgment.
- Patient who has a positive pregnancy test at screening or on the pretest day, is pregnant, or plans to become pregnant during the course of the trial and up to 90 days after GH001 dosing.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description GH001 Individualized Dosing Regimen GH001 Drug: 5-Methoxy-N,N-Dimethyltryptamine GH001 is administered via inhalation, as an IDR (individualized dosing regimen) consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience \[PE\]) at the previously administered dose
- Primary Outcome Measures
Name Time Method The anti-depressive effects of GH001 evaluated by the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) assessed at Day 7 From Baseline to Day 7 The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6. The overall score ranges from 0 to 60
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Amsterdam UMC
🇳🇱Amsterdam, Netherlands
Clerkenwell Health
🇬🇧London, United Kingdom
St. Pancras Clinical Research
🇬🇧London, United Kingdom
Sheffield Health and Social Care NHS Foundation
🇬🇧Sheffield, United Kingdom